MedPath

Arabic Gum-Absorption Study

Not Applicable
Completed
Conditions
Bioavailability
Interventions
Dietary Supplement: menaquinone-7 from arabic gum capsules
Dietary Supplement: menaquinone-7 from casein capsules
Dietary Supplement: menaquinone-7 from linseed oil capsules
Registration Number
NCT00858767
Lead Sponsor
Maastricht University Medical Center
Brief Summary

Previous studies have indicated that menaquinone-7 (MK-7) is the most effective form of vitamin K. The Japanese soya product natto is one of the richest food sources of MK-7, but its taste is not appreciated by the Western society. For this reason, the active biological compound has been manufactured as enriched oil or casein (≈80% of proteins in cow's milk)-enriched powder. However, cow's milk allergy is the most common cause of food allergy affecting a minimum of 2-3% of infants. The investigators will therefore compare this protein-delivery system to an alternative delivery system (Arabic gum; 98% polysaccharides). To compare the difference between powder and oil as MK-7 delivery vehicle, the investigators will also test the efficacy of enriched linseed oil.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
69
Inclusion Criteria
  • Healthy men and women aged between 20 and 40 y
  • Normal body weight and height (BMI <30 kg/m2)
  • Stable body weight (weight gain or loss <3 kg in past 3 mo)
  • Caucasian race
  • Written consent to take part in the study
  • Low vitamin K status
Exclusion Criteria
  • (A history of) metabolic or gastrointestinal diseases
  • Chronic degenerative and/or inflammatory diseases
  • Abuse of drugs and/or alcohol
  • Use of corticosteroids
  • Use of oral anticoagulants
  • (A history of) soy allergy
  • Use of vitamin K-containing multivitamins or vitamin K supplements
  • Anaemia
  • Blood donation or participation in another study within one month before the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2menaquinone-7 from arabic gum capsules2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
1menaquinone-7 from casein capsules2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
3menaquinone-7 from linseed oil capsules2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
Primary Outcome Measures
NameTimeMethod
serum level menaquinone-78 weeks
Secondary Outcome Measures
NameTimeMethod
plasma level of biochemical markers carboxylated matrix-Gla protein, undercarboxylated matrix-Gla protein, carboxylated osteocalcin, undercarboxylated osteocalcin8 weeks

Trial Locations

Locations (1)

VitaK BV /University of Maastricht

🇳🇱

Maastricht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath